Penpulimab vs Serplulimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Penpulimab

Marketed by Akeso and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03866993 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled Phase 3 trial in 350 patients with advanced squamous non-small-cell lung cancer, all of whom also received paclitaxel and carboplatin. An independent radiology committee assessed progression-free survival in two primary populations: all randomized patients and the PD-L1-positive subgroup. Penpulimab improved progression-free survival in both populations (median 7.6 vs 4.2 months overall and 8.1 vs 4.2 months in PD-L1-positive patients, both p<0.0001), so the trial met its primary endpoint. The figures come from the peer-reviewed Lancet Respiratory Medicine paper.

Reported efficacy

Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1 (Up to approximately 2 years); PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1 (Up to approximately 2 years): Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. (met)

Result source: NCT03866993

Serplulimab

Marketed by Shanghai Henlius Biotech and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Weak signal

NCT05807893 · Phase 2/3 · completed

The study treated 40 participants in a non-randomized, open-label, single-arm design without a comparator group. Its primary endpoint was intracranial progression-free survival. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: June 2027 · NCT07253142 (registry estimate)

Reported efficacy

tumor assessment (Baseline until disease progression or death, whichever occurs first (up to approximately 24months)): At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67). (met)

Result source: NCT04033354

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointPenpulimabSerplulimab
PFS, median8.6 vs 4.2a+4.4 vs placeboNCT03866993—Not posted · NCT05807893
OS, median—Not posted · NCT03866993—Not posted · NCT05807893
ORR—Not posted · NCT03866993—Not posted · NCT05807893
Duration of response, median—Not posted · NCT03866993—Not posted · NCT05807893

PFS, median

Penpulimab
8.6 vs 4.2a+4.4 vs placeboNCT03866993
Serplulimab
—Not posted · NCT05807893

OS, median

Penpulimab
—Not posted · NCT03866993
Serplulimab
—Not posted · NCT05807893

ORR

Penpulimab
—Not posted · NCT03866993
Serplulimab
—Not posted · NCT05807893

Duration of response, median

Penpulimab
—Not posted · NCT03866993
Serplulimab
—Not posted · NCT05807893
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Penpulimab

PFS 8.6 vs 4.2 placebo months
time to event · months
NCT03866993 · Phase 3 · sponsor-reported, not registry data

Serplulimab

Intracranial PFS 13.1 months
absolute value · months
No placebo or comparator arm
NCT05807893 · Phase 2/3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Penpulimab's landscape · Serplulimab's landscape